Evidence map›Paper›PMID 25184687›Full record

ArticleAmerican journal of respiratory and critical care medicine2014

The role of bacteria in the pathogenesis and progression of idiopathic pulmonary fibrosis.

Phillip L Molyneaux, Michael J Cox, Saffron A G Willis-Owen, Patrick Mallia, Kirsty E Russell, Anne-Marie Russell, Elissa Murphy, Sebastian L Johnston, David A Schwartz, Athol U Wells and 3 more

Registry-linked trialAbstract read
In one paragraph

Article in American journal of respiratory and critical care medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05674994 (Glucocorticoids Versus Placebo for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis), which is not on this map. Cited by 326 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
326citing papers in PubMed, 7 pooled it
35.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05674994 phase3recruitingnot on this mapstarted 2023, after this paper: background citation

Glucocorticoids Versus Placebo for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis: a Randomized Controlled Trial

TypeinterventionalSponsorFondation Hôpital Saint-JosephRan2023 to 2026Enrolled110ConditionsAcute Exacerbation of Idiopathic Pulmonary FibrosisArmsMethylprednisone/Prednisone, Placebo
3 · Its place in the literature

Who cites it

326 citing papers in PubMed, 7 syntheses or guidelines pooled it, 547 citations in OpenAlex.

  1. Pooled it
  2. Intestinal microbiota and biliary system diseases.Frontiers in cellular and infection microbiology · 2024
    Pooled it
  3. Pooled it
  4. The Human Respiratory Microbiome: Current Understandings and Future Directions.American journal of respiratory cell and molecular biology · 2023
    Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Article
  11. Review
  12. Gut microbiota associate with disease severity and survival in idiopathic pulmonary fibrosis.American journal of respiratory and critical care medicine · 2026
    Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

266 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Phillip L Molyneaux1 National Heart and Lung Institute, Imperial College, London, United Kingdom.
Michael J Cox
Saffron A G Willis-Owen
Patrick Mallia
Kirsty E Russell
Anne-Marie Russell
Elissa Murphy
Sebastian L Johnston
David A Schwartz
Athol U Wells
William O C Cookson
Toby M Maher
Miriam F Moffatt
Imperial College London · GBNational Institute for Health Research · GBNational Health Service · GBUniversity of Colorado Denver · US

Funding

Mechanisms of Familial Pulmonary FibrosisP01HL092870 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BLACKWELL, TIMOTHY S. · 2010 to 2020
$21.6M
Role of Genetics in Idiopathic Pulmonary Fibrosis (IPF)R01HL097163 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI FINGERLIN, TASHA E., SCHWARTZ, DAVID ALBERT · 2009 to 2018
$16.4M
Functional Genetics in Idiopathic Pulmonary FibrosisR33HL120770 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI SCHWARTZ, DAVID ALBERT · 2016 to 2018
$1.6M
Medical Research Council G0600879Medical Research Council G1000758NHLBI NIH HHS HL092870NHLBI NIH HHS HL097163NHLBI NIH HHS P01 HL092870NHLBI NIH HHS R01 HL097163NHLBI NIH HHS R33 HL120770Wellcome Trust 097117
6 · The paper itself

Abstract

rationaleIdiopathic pulmonary fibrosis (IPF) is a progressive lung disease of unknown cause that leads to respiratory failure and death within 5 years of diagnosis. Overt respiratory infection and immunosuppression carry a high morbidity and mortality, and polymorphisms in genes related to epithelial integrity and host defense predispose to IPF.

objectivesTo investigate the role of bacteria in the pathogenesis and progression of IPF.

methodsWe prospectively enrolled patients diagnosed with IPF according to international criteria together with healthy smokers, nonsmokers, and subjects with moderate chronic obstructive pulmonary disease as control subjects. Subjects underwent bronchoalveolar lavage (BAL), from which genomic DNA was isolated. The V3-V5 region of the bacterial 16S rRNA gene was amplified, allowing quantification of bacterial load and identification of communities by 16S rRNA quantitative polymerase chain reaction and pyrosequencing. MEASUREMENTS AND MAIN

resultsSixty-five patients with IPF had double the burden of bacteria in BAL fluid compared with 44 control subjects. Baseline bacterial burden predicted the rate of decline in lung volume and risk of death and associated independently with the rs35705950 polymorphism of the MUC5B mucin gene, a proven host susceptibility factor for IPF. Sequencing yielded 912,883 high-quality reads from all subjects. We identified Haemophilus, Streptococcus, Neisseria, and Veillonella spp. to be more abundant in cases than control subjects. Regression analyses indicated that these specific operational taxonomic units as well as bacterial burden associated independently with IPF.

conclusionsIPF is characterized by an increased bacterial burden in BAL that predicts decline in lung function and death. Trials of antimicrobial therapy are needed to determine if microbial burden is pathogenic in the disease.

Indexed as

MicrobiotaAgedBacteriaBacterial LoadBronchoalveolar LavageBronchoalveolar Lavage FluidBronchoscopyCase-Control StudiesDisease ProgressionDNA, BacterialFemaleGenetic MarkersGenotyping TechniquesHumansIdiopathic Pulmonary FibrosisLogistic ModelsDNA, BacterialGenetic MarkersMUC5B protein, humanMucin-5Bbacteriaidiopathic pulmonary fibrosismicrobiomeMuc5b

Identifiers

PMID25184687
PMCPMC4299577
OpenAlexW2103221430

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.